SynthesisPloS one2021
Recurrent SARS-CoV-2 infections and their potential risk to public health - a systematic review.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Pathogen priming alters host transmission potential and predictors of transmissibility in a wild songbird species.mSphere · 2025Article
- Pathogen priming alters host transmission potential and predictors of transmissibility in a wild songbird species.bioRxiv : the preprint server for biology · 2024Article
- Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals.Open forum infectious diseases · 2024Article
- SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.The Journal of infectious diseases · 2023Article
- Evidence of SARS-CoV-2 reinfection: analysis of 35,000 subjects and overview of systematic reviews.Clinical and experimental medicine · 2023Article
- Clinical characteristics and risks of the convalescent COVID-19 patients with re-detectable positive RNA test: a 430 patients with Omicron infected cross-sectional survey in Tianjin, China.Journal of infection and public health · 2022Article
- Microfluidic bioprinting of tough hydrogel-based vascular conduits for functional blood vessels.Science advances · 2022Article
- SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.Environmental research · 2022Review
- Post-COVID-19 health-care utilization: one year after the 2020 first wave in Brunei Darussalam.Western Pacific surveillance and response journal : WPSARObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo inform quarantine and contact-tracing policies concerning re-positive cases-cases testing positive among those recovered. MATERIALS AND
methodsWe systematically reviewed and appraised relevant literature from PubMed and Embase for the extent of re-positive cases and their epidemiological characteristics.
resultsIn 90 case reports/series, a total of 276 re-positive cases were found. Among confirmed reinfections, 50% occurred within 90 days from recovery. Four reports related onward transmission. In thirty-five observational studies, rate of re-positives ranged from zero to 50% with no onward transmissions reported. In eight reviews, pooled recurrence rate ranged from 12% to 17.7%. Probability of re-positive increased with several factors.
conclusionRecurrence of a positive SARS-CoV-2 test is commonly reported within the first weeks following recovery from a first infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.